Calendario›GNPX›DOTAP:Chol-TUSC2

DOTAP:Chol-TUSC2

TUSC2-nanoparticles and Erlotinib in Stage IV Lung Cancer

Ensayo de Genprex, Inc. en Cancer de pulmon.

Más ensayos de: Cáncer de pulmón.

Fase

Fase 1/2

Estado

Interrumpido

Participantes

25

previstos

Centros

1

Fin del objetivo primario

oct 2016

fecha real

Qué significa cada fase y cada estado.

Estudio de intervención, de un solo grupo, abierto. Comenzó en feb 2014.

Este ensayo se detuvo. Motivo declarado por el promotor (del registro, en inglés): «Trial terminated by sponsor after decision to evaluate combination of quaratusugene ozeplasmid and osimertinib instead of further evaluating quaratusugene ozeplasmid and erlotinib.».

Qué mide

Maximum Tolerated Dose (MTD) Level for Drug Treatment Combination (First 21 day cycle) (del registro, en inglés)

Cómo lo describe el promotor

En el documentoEn inglés, del registroThe goal of phase 1 of this clinical research study is to find the highest dose of DOTAP:Chol-TUSC2 that can be safely given in combination with Tarceva (erlotinib hydrochloride) to patients with NSCLC. The goal of phase 2 of this clinical research study is to learn if the combination of DOTAP:Chol-TUSC2 and erlotinib hydrochloride can help to control NSCLC. The safety of this drug combination will also be studied in both phases. DOTAP:Chol-TUSC2 (previously FUS1) is a drug that helps transfer a gene called TUSC2 into cancer cells. Researchers think that cells without this gene may be involved in the development of lung cancer tumors. They want to find out if replacing the gene in these cells may keep the tissue from forming cancer cells. Erlotinib hydrochloride is designed to block a protein on tumor cells that may control tumor growth and survival. This may stop tumors from growing.

Más ensayos de GNPX

Todos los de GNPX, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT01455389), actualizada en feb 2022.